Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
China Health Industries Holdings, Inc. (CHHE)
Harbin, CN
Operating through its various subsidiaries, China Health Industries Holdings, Inc. specializes in the production and distribution of a comprehensive array of health-oriented goods. Its product portfolio features numerous hemp-derived items, including hemp oil, protein powders, polypeptides, and a selection of skincare solutions like essence repair lotions, revitalizing essences, anti-aging brightening eye creams, and nourishing creams designed to combat signs of aging. The company also supplies dietary supplements, such as the QunLe brand's Sailuozhi soft capsules, which combine frog oil, soybean isoflavone, procyanidine, and vitamin E to help reduce freckles and enhance skin moisture. Another key offering is the Kindlink brand's propolis and black ant capsules, formulated with propolis, black ant, acanthopanax, and astragalus root. Beyond these, China Health Industries provides a range of health products addressing specific concerns like acne treatment, relief from eye strain, boosting bone density, improving memory, combating nutritional anemia and chloasma, promoting digestive health and lead detoxification, bolstering immunity, alleviating physical fatigue, and diminishing chloasma, alongside essential iron and multi-vitamin and mineral supplements. Additionally, the firm is involved in the manufacturing and sale of various medical drugs. The distribution of its extensive product line is primarily managed through a network of sales agents. China Health Industries Holdings, Inc. maintains its base of operations in Harbin City, People's Republic of China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | -99.95% | -99.93% | -99.96% | -99.94% | -99.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+41,689.9% ★ Q1'24: -99.6% (vs Q1'23)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-14.8% Q1'24: +50.0% (vs Q1'23)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-39,177.1% Q1'24: +3,837.9% (vs Q1'23)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-1,651.7% Q1'24: -163,512.6% (vs Q1'23)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-4.2% Q1'24: -18.2% (vs Q1'23)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q1'24: +0.0% (vs Q1'23)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-4.46× Q1'24: -19.08× (vs Q1'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Ownership Overview
Ownership breakdown not available.
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Xin | 24.06M | 53.80% | 24.06M | — | 24.06M | 10.00 | IN | China | 2007-11-06 | ↗ |
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2015-03-30 | Xin Sun | Director / Officer / 10% Owner | A-Award | A | Common Stock, par value $0.0001 | 3,000,000 | 0.00 | — | 20,507,188 | — | ↗ |
| 2013-08-21 | Xin Sun | Director / Officer / 10% Owner | D-Return | D | Common Stock, par value $0.0001 | 15,495,900 | 0.49 | 7.59M | 17,507,188 | — | ↗ |
| 2009-04-07 | Xin Sun | Director / Officer / 10% Owner | D-Return | D | Common Stock | 28,200,000 | 0.00 | — | 33,003,088 | — | ↗ |
| 2008-12-31 | Xin Sun | Director / Officer / 10% Owner | J-Other | A | Common stock, par value $.0001 per share | 60,000,000 | 0.00 | — | 61,023,088 | — | ↗ |
| 2007-09-10 | Xin Sun | Director / Officer / 10% Owner | — | D | Common Stock, $0.0001 par value | 0 | 0.00 | — | 24,061,745 | — | ↗ |
| 2005-08-26 | EWING HALL E | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 34,800 | — | ↗ |
| 2005-08-16 | Robinson Jack C | Director | — | D | Common Stock | 0 | 0.00 | — | 10,000 | — | ↗ |
| 2005-07-25 | Hahn Brian Lee | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 30,000 | — | ↗ |
| 2005-07-25 | Foster Teri S | Director | — | D | Common Stock | 0 | 0.00 | — | 50,000 | — | ↗ |
| 2005-05-10 | McKee Dennis | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 2,000,000 | — | ↗ |
| 2005-05-10 | Bontems Thomas Allen | Director / Officer / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 23,460,000 | — | ↗ |
| 2005-04-08 | Bontems Thomas Allen | Officer / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 100,000 | — | ↗ |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Sun Xin | Chairman, Chief Executive Officer, Chief Financial Officer & Treasurer | 12.5K | male |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CHHE
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
